Skip to content
Politically.com Search all
Menu

2026 · 3rd Quarter (July 1 - Sep 30)

ASSOCIATION OF ACCESSIBLE MEDICINES

Filed by MEHLMAN CONSULTING, INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-10-28 06:26:13 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 20, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
bebca4b5-0987-4e5e-8c1e-183aa7605543
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Issues related to generic medicines.

HCR · Health Issues

Issues related to generic and biosimilar medications.

PHA · Pharmacy

Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling. H.R. 9661/S. 1414 - Expediated Access to Biosimilars Act.

Literal federal measure citations: S. 1040, H.R. 5526, S. 1954, H.R. 3269, S. 43, H.R. 1843, S. 1302, H.R. 9661, S. 1414

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.